Literature DB >> 3192178

Relative risks of death due to liver disease among Japanese male adults having various statuses for hepatitis B s and e antigen/antibody in serum: a prospective study.

K Sakuma1, N Saitoh, M Kasai, H Jitsukawa, I Yoshino, M Yamaguchi, K Nobutomo, M Yamumi, F Tsuda, T Komazawa.   

Abstract

Taking advantage of the compulsory annual medical check-up at the Central Institute of Health, Japan National Railways, hepatitis B seromarkers were tested in male employees at work and their "dead and alive" status was followed for more than 6 years for their prognostic significance. Two prospective studies were carried out. In the first study, two groups (cohorts) of males age 40 to 55 years were tested in 1973 and 1978, respectively, for HBsAg and anti-HBs. The relative risk of dying from primary liver cancer in HBsAg-positive carriers (n = 126) as compared to the controls who were negative for both HBsAg and anti-HBs (n = 5,322) was 30.03 and significantly high, whereas those positive for anti-HBs (n = 1,470) had no increased risk of dying from primary liver cancer or from other liver diseases. The follow-up period ranged from 6.5 to 11.5 years, averaging 8.5 years. In the second study, three male cohorts of the same ages were tested for HBsAg and HBeAg/anti-HBe (micro-Ouchterlony method) in 1977, 1978 and 1979, respectively. There were 513 HBsAg-positive carriers among 25,547 examinees, who were followed for an average of 7.3 (6 to 8) years. Among these HBsAg carriers, those who were positive for HBeAg on entry had the highest risk of dying from primary liver cancer (relative risk, 50.25) and from other liver diseases (78.06), followed by those negative for both (28.95 and 21.78, respectively) and those positive for anti-HBe (9.47 and 6.43) when compared with 25,034 noncarriers.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3192178     DOI: 10.1002/hep.1840080628

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  20 in total

1.  Indications for referral and assessment in adult liver transplantation: a clinical guideline. British Society of Gastroenterology.

Authors:  J Devlin; J O'Grady
Journal:  Gut       Date:  1999-12       Impact factor: 23.059

2.  Routine hepatitis B immunization in India: cost effectiveness needs reassessment.

Authors:  Jacob M Puliyel; Riju Mittal; Vineet Tyagi; Sangeeta Gupta
Journal:  Indian J Pediatr       Date:  2003-02       Impact factor: 1.967

3.  Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults.

Authors:  S D Ryder
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

Review 4.  Hepatocellular carcinoma. A worldwide problem and the major risk factors.

Authors:  R G Simonetti; C Cammà; F Fiorello; F Politi; G D'Amico; L Pagliaro
Journal:  Dig Dis Sci       Date:  1991-07       Impact factor: 3.199

5.  Updates in the management of hepatocellular carcinoma.

Authors:  Robert Wong; Catherine Frenette
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-01

Review 6.  Hepatocellular carcinoma prevention: a worldwide emergence between the opulence of developed countries and the economic constraints of developing nations.

Authors:  Francesca Lodato; Giuseppe Mazzella; Davide Festi; Francesco Azzaroli; Antonio Colecchia; Enrico Roda
Journal:  World J Gastroenterol       Date:  2006-12-07       Impact factor: 5.742

7.  Extensive oxidative DNA damage in hepatocytes of transgenic mice with chronic active hepatitis destined to develop hepatocellular carcinoma.

Authors:  T M Hagen; S Huang; J Curnutte; P Fowler; V Martinez; C M Wehr; B N Ames; F V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

8.  Multivariate analysis of risk factors for hepatocellular carcinoma in patients with hepatitis C virus-related liver cirrhosis.

Authors:  T Chiba; Y Matsuzaki; M Abei; J Shoda; T Aikawa; N Tanaka; T Osuga
Journal:  J Gastroenterol       Date:  1996-08       Impact factor: 7.527

9.  Chronic hepatitis B infection in Canada.

Authors:  G Y Minuk; J Uhanova
Journal:  Can J Infect Dis       Date:  2001-11

Review 10.  The detection of hepatitis B virus (HBV) in HBsAG negative individuals with primary liver cancer.

Authors:  P Paterlini; C Bréchot
Journal:  Dig Dis Sci       Date:  1991-08       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.